Abstracts tagged "Cardiovascular disease"

Abstract Number: 2883 • 2017 ACR/ARHP Annual Meeting
Prevalence of Cardiovascular Risk Factors and Subclinical Cardovacular Disease in Psoriatic Arthritis
María Paz Martínez-Vidal¹, Cristina Fernández-Carballido², Mariano Andres³, Vega Jovaní⁴, Carlos Santos⁵, Maria Nieves Martínez Alberola⁶, Francisca Sivera⁷ and Raquel Martin-domenech⁶, ¹Rheumatology, Hospital general universitario de Alicante, Alicante, Spain, ²Hospital General Universitario de Elda, Elda, Spain, ³RHEUMATOLOGY, Hospital general universitario de Alicante, Alicante, Spain, ⁴Reumatología, Hospital general universitario de Alicante, Alicante, Spain, ⁵Rheumatology, Hospital de Alcoy, Alcoy, Spain, ⁶Rheumatology, Hospital General Universitario de Elda, Elda, Spain, ⁷Sección de Reumatología, Hospital General Universitario de Elda., Elda, Spain
Background/Purpose: SCORE tables underestimate the Cardiovascular Risk (CVR) for patients with Rheumatoid Arthritis (RA) and EULAR recommends multiplying by 1.5 the CVR obtained from them…
Abstract Number: 28 • 2017 Pediatric Rheumatology Symposium
Dyslipidemia in Juvenile Dermatomyositis
Arya Kadakia¹, Amer Khojah², Gabrielle A. Morgan^3,4, Megan L. Curran⁵, Irwin Benuck⁶, Chinag-Ching Huang¹, Dong Xu⁷ and Lauren M. Pachman^8,9, ¹Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ²Division of Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ³Cure JM Program of Excellence in Myositis Research, Chicago, IL, ⁴Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁵Pediatric Rheumatology, Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, IL, ⁶Division of Cardiology, Northwestern University Feinberg School of Medicine, Department of Pediatrics, Chicago, IL, ⁷Program of Excellence in Cure-Juvenile Myositis (JM) Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁸Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁹Rheumatology/Immunology, Ann & Robert H. Lurie Children's Hosptial of Chicago, Chicago, IL
Background/Purpose: Juvenile Dermatomyositis (JDM) is a multisystem pediatric autoimmune disease characterized by chronic inflammation of muscle and skin. Premature atherosclerosis is an important cause of…
Abstract Number: 21 • 2017 Pediatric Rheumatology Symposium
Enhancing Quality of Care in Childhood-Onset Systemic Lupus Erythematosus by Improving Performance on Quality Indicator Measures in Cardiovascular and Bone Health
Emily A. Smitherman¹, Adam Furnier², Janalee Taylor³, Mary Beth Burns⁴, Hermine Brunner⁵ and Esi Morgan¹, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Rheumatology, PRCSG, Cincinnati, OH
Background/Purpose: Childhood-onset SLE (cSLE) leads to poor health outcomes, including cardiovascular and bone health, due to high rates of potentially devastating disease complications and medication…
Abstract Number: 1L • 2016 ACR/ARHP Annual Meeting
The Cardiovascular Safety of Celecoxib Versus Ibuprofen or Naproxen in 24,081 Patients with Osteoarthritis or Rheumatoid Arthritis
M. Elaine Husni¹, Daniel H. Solomon², Katherine E Wolski³, Lisa M Wisniewski³, Steven E Nissen⁴ and on behalf of the PRECISION Trial Investigators, ¹Rheumatology, Cleveland Clinic, Cleveland, OH, ²Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, ⁴Cardiovascular Medicine, Chair, Cleveland Clinic, Cleveland, OH

*Both authors (Husni, Solomon)　contributed equally and will co present Background/Purpose: The relative cardiovascular (CV) safety of non-selective NSAIDs and selective COX-2 NSAIDs remains unclear. Given…
Abstract Number: 22 • 2016 ACR/ARHP Annual Meeting
Incidence and Factors Associated with the Development of Non Alcoholic Fatty Liver Disease(NAFLD) Among Patients with Rheumatoid Arthritis
Ani John¹, Angela Witt Prehn², Hebatullah Tawfik², George W. Reed³ and Joel Kremer⁴, ¹School of Health Sciences, Walden University, Minneapolis, CA, ²School of Health Sciences, Walden University, Minneapolis, MN, ³Corrona, LLC, Southborough, MA, ⁴The Center for Rheumatology, Albany Medical College, Albany, NY
Background/Purpose: NAFLD is a leading cause of chronic liver disorders, unrelated to significant alcohol use. RA and NAFLD have shared risk factors such as age,…
Abstract Number: 743 • 2016 ACR/ARHP Annual Meeting
Long-Term Hydroxychloroquine Therapy and Low-Dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus
Serena Fasano¹, Michele Iudici², Ilenia Pantano³, Luciana Pierro³ and Gabriele Valentini⁴, ¹Internal and Experimental Medicine Naples, Italy, Rheumatology Unit, Second University of Naples, Naples, Italy, ²National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ³Rheumatology Unit, Second University of Naples, Naples, Italy, ⁴Internal and Experimental Medicine, Rheumatology Unit, Second University of Naples, Naples, Italy
Background/Purpose: Hydroxychloroquine (HCQ) is a mainstay of treatment in patients with SLE. It has been demonstrated to reduce disease activity and prevent damage accrual and…
Abstract Number: 1468 • 2016 ACR/ARHP Annual Meeting
Increased Mitral and Tricuspid Valve Regurgitation Among Mexican Mestizo Patients with Rheumatoid Arthritis
Dionicio A. Galarza-Delgado¹, Jose Ramon Azpiri-Lopez², Iris J. Colunga-Pedraza¹, Rosa I. Arvizu-Rivera³, Adrian Martinez-Moreno⁴, Luis E. Gonzalez-Carrillo⁴, Miguel A. Ramos-Guzman⁴, Filiberto Hervert-Cavazos⁴, Alberto Cardenas-de La Garza¹, Raymundo Vera-Pineda⁵, Mario Alberto Garza-Elizondo¹ and Mario Alberto Benavides-González⁴, ¹Rheumatology, Hospital Universitario, UANL., Monterrey, Mexico, ²Cardiology, Hospital Universitario, UANL., Monterrey, Mexico, ³Rheumatology, Hospital Universitario UANL, Monterrey, Mexico, ⁴Cardiology, Hospital Universitario UANL, Monterrey, Mexico, ⁵Cardiology., Hospital Universitario, UANL., Monterrey, Mexico
Background/Purpose: Rheumatoid arthritis (RA) is chronic, systemic, inflammatory, multifactorial disease that mainly affects synovial joints. RA-patients have an increased risk of cardiovascular (CV) morbidity and…
Abstract Number: 1524 • 2016 ACR/ARHP Annual Meeting
Suppletion Therapy May be Warranted in RA Patients with Co-Existent Subclinical Hypothyroidism
Rabia Agca^1,2, Hennie Raterman², Suat Simsek³, Alexandre E. Voskuyl² and Mike T. Nurmohamed^1,4, ¹Rheumatology, Amsterdam Rheumatology and immunology Center, Location Reade, Amsterdam, Netherlands, ²Rheumatology, Amsterdam Rheumatology and immunology Center, Location VU University Medical Center, Amsterdam, Netherlands, ³Internal Medicine, Noodwest Ziekenhuisgroep, Location Alkmaar, Alkmaar, Netherlands, ⁴Rheumatology, Amsterdam Rheumatology and immunology Center, Location VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands
Background/Purpose: Autoimmune thyroid disease often coexists with RA and has been associated with an elevated cardiovascular (CV) risk, especially in hypothyroid patients. However, the existing…
Abstract Number: 2289 • 2016 ACR/ARHP Annual Meeting
Obesity and Echocardiographic Changes in the Different Stages of Gout
Rada Gancheva¹, Atanas Kundurdjiev², Mariana Ivanova¹, Todor Kundurzhiev³ and Zlatimir Kolarov¹, ¹Medical Faculty, Medical University, University Hospital "St. Iv. Rilski", Clinic of Rheumatology, Sofia, Bulgaria, ²Medical Faculty, Medical University, University Hospital "St. Iv. Rilski", Clinic of Nephrology, Sofia, Bulgaria, ³Medical University, Faculty of Public Health, Sofia, Bulgaria
Background/Purpose: Studies on gout and its stages as a cardiovascular (CV) risk factor are few and with contradictory results. We compared echocardiographic parameters, known as…
Abstract Number: 24 • 2016 ACR/ARHP Annual Meeting
Modifiable Rheumatoid Arthritis Factors and Impact on Cardiovascular Risk
Katherine Liao¹, Carol J. Etzel^2,3, Jeffrey D. Greenberg⁴, Hongshu Guan⁵, Joel Kremer⁶ and Daniel H. Solomon⁷, ¹Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, ²Departments of Epidemiology and Biostatistics, University of Texas School of Public Health, Houston, TX, ³Corrona, LLC, Southborough, MA, ⁴New York University School of Medicine, New York, NY, ⁵Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁶The Center for Rheumatology, Albany Medical College, Albany, NY, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Cardiovascular disease (CVD) is a major source of morbidity and mortality in RA, but current management goals follow general population recommendations without tailoring based…
Abstract Number: 860 • 2016 ACR/ARHP Annual Meeting
Assessment of the Frequency of Cardiovascular Risk Factors in Patients with Takayasu’s Arteritis
Fatma Alibaz-Oner¹, Matthew J. Koster², Ali Ugur Unal³, Hale Gulcin Yildirim⁴, Ceylan Cikikci⁴, Cynthia S. Crowson⁵, Ashima Makol⁶, Steven R. Ytterberg⁶, Eric L. Matteson⁶, Haner Direskeneli⁷ and Kenneth J. Warrington⁶, ¹Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ²Rheumatology, University of California Los Angeles, CA, USA Mayo Clinic, Rochester, MN, ³Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, ⁴Marmara University Faculty of Medicine, Istanbul, Turkey, ⁵Health Sciences Research, Mayo Clinic, Rochester, MN, ⁶Rheumatology, Mayo Clinic, Rochester, MN, ⁷Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: Accelerated atherosclerosis associated with chronic inflammation is one of the major complications of systemic inflammatory diseases. Takayasu arteritis (TAK) is a rare, systemic large-vessel…
Abstract Number: 1469 • 2016 ACR/ARHP Annual Meeting
Coronary Territories Are Not Affected in Mexican Mestizo Patients with Rheumatoid Arthritis in Comparison to Matched Controls: Evaluation Using Speckle Tracking Echocardiography
Dionicio A. Galarza-Delgado¹, Iris J. Colunga-Pedraza^2,3,4, Jose Ramon Azpiri-Lopez⁵, Adrian Martinez-Moreno⁶, Rosa I. Arvizu-Rivera², Raymundo Vera-Pineda⁷, Alberto Cardenas-de La Garza³, Mario Alberto Garza-Elizondo⁸, Mario Alberto Benavides-González⁶, Miguel A. Ramos-Guzman⁶, Luis E. Gonzalez-Carrillo⁶ and Filiberto Hervert-Cavazos⁶, ¹Internal Medicine/Rheumatology, Hospital Universitario UANL, Monterrey, Mexico, ²Rheumatology, Hospital Universitario UANL, Monterrey, Mexico, ³Rheumatology, Hospital Universitario, UANL., Monterrey, Mexico, ⁴Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁵Cardiology, Hospital Universitario, UANL., Monterrey, Mexico, ⁶Cardiology, Hospital Universitario UANL, Monterrey, Mexico, ⁷Cardiology., Hospital Universitario, UANL., Monterrey, Mexico, ⁸Rheumatology, Hospital Universitario UANL., Monterrey, N.L., Mexico
Background/Purpose: Atherosclerotic cardiovascular disease is the leading cause of death in patients with rheumatoid arthritis (RA). Two dimensional speckle tracking echocardiography (TSE) assess local and…
Abstract Number: 1562 • 2016 ACR/ARHP Annual Meeting
Interaction Between Antibodies to Paraoxonase 1 and PON1 rs662 Polymorphism: New Clues to Understand HDL Dysfunction and Oxidative Stress in Rheumatoid Arthritis
Javier Rodríguez-Carrio¹, Mercedes Alperi-López², Raquel López-Mejías³, Patricia López¹, Francisco Javier Ballina-García², Francisco Abal⁴, Miguel Angel Gonzalez-Gay^3,5 and Ana Suárez¹, ¹Area of Immunology, Department of Functional Biology, University of Oviedo, Oviedo, Spain, ²Department of Rheumatology, Hospital Universitario Central de Asturias, Asturias, Spain, ³Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, ⁴Centro de Salud Sariego, Siero, Servicio de Salud del Principado de Asturias (SESPA), Siero, Spain, ⁵School of Medicine, University of Cantabria, Santander, Spain
Background/Purpose: Traditional and non-traditional cardiovascular (CV) risk factors underlie CV disease occurrence in rheumatoid arthritis (RA). Recently, a functional impairment of HDL antioxidant capacity has…
Abstract Number: 2290 • 2016 ACR/ARHP Annual Meeting
Crystal-Proven Gout and Disease Severity Factors Influencing the Prevalence of Cardiovascular Diseases
I.J.M. Disveld^1,2, J. Fransen³, L.B.E. Kienhorst⁴, H.J.E.M. Janssens⁵, S. Zoakman¹, A.J.W. Branten¹, C.M.A. de Gendt¹, A.J.L. de Jong⁶, H. Visser⁷ and M. Janssen¹, ¹Department of Rheumatology, Rijnstate Hospital Arnhem, Arnhem, Netherlands, ²Radboudumc Nijmegen, Nijmegen, Netherlands, ³Department of Rheumatolgy, Radboudumc Nijmegen, Nijmegen, Netherlands, ⁴UMC Utrecht, Utrecht, Netherlands, ⁵Rijnstate Hospital Arnhem, Arnhem, Netherlands, ⁶Department of Rheumatology, Rijnstate Arnhem, Arnhem, Netherlands, ⁷Department of Rheumatolgy, Rijnstate Hospital Arnhem, Arnhem, Netherlands
Background/Purpose: Gout is a health disorder affecting many patients worldwide. Clinical gout studies showed a high prevalence of cardiovascular diseases (CVD), raising the question whether…
Abstract Number: 29 • 2016 ACR/ARHP Annual Meeting
Risk of Vascular Mortality in Seniors with New-Onset Rheumatoid Arthritis
Jessica Widdifield¹, Michael Paterson², Anjie Huang³, Bindee Kuriya⁴, Carter Thorne⁵, Janet E. Pope⁶, Claire Bombardier⁷ and Sasha Bernatsky⁸, ¹McGill University, Toronto, ON, Canada, ²Institute of Clinical Evaluative Sciences, Toronto, ON, Canada, ³Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ⁴Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵University of Toronto and Southlake Regional Health Centre, Newmarket, ON, Canada, ⁶University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ⁷University of Toronto, Toronto, ON, Canada, ⁸Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: RA patients are known to be at increased risk of vascular morbidity and mortality, although conflicting reports exist for incident RA patients. Our aim…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].